MoneyWorks4Me

Biocon informs about updates

15 Jun 2024 Evaluate

Biocon has informed that the US Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 6), located at Visakhapatnam, Andhra Pradesh, on 14 June 2024. Three observations were cited at the end of the Inspection, which they will be addressing within the stipulated time. Biocon stands committed to Quality, Safety & Efficacy of the products manufactured. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.


Peers
Company Name CMP
Sun Pharma. Inds. 1795.85
Dr. Reddys Labs. 1195.45
Cipla 1327.05
Lupin 2019.50
Zydus Lifesciences 1141.60
View more..